Baiyunshan Builds Pipeline Library of Over 100 Projects, Completes Initiation of More Than 10 In-Licensed
Baiyunshan disclosed at its 2026 interim results briefing held on September 14, 2026, that the company has built a pipeline project library of more than 100 items and has conducted due diligence on nearly 50 business-development (BD) innovative drug projects, of which more than 10 in-licensed innovative drug pipeline programs have completed project initiation.
The in-licensed innovative drug pipeline programs that have completed project initiation cover multiple key clinical demand areas and frontier fields.
The company said it will continue to actively advance related BD work and fulfill its disclosure obligations in a timely manner.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Pharmaceuticals, with intensity 50/100 and 60% confidence over a medium term horizon.
Pharmaceuticals
- Direction
- positive
- Intensity
- 50
- Confidence
- 60%
- Horizon
- Medium term
Pharmaceutical R&D Services
- Direction
- positive
- Intensity
- 40
- Confidence
- 55%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.